Latest
TipRanks Earnings
Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 1–21
- Headlines
- 21
- Sources here
- 5
- Companies here
- 12
Current section
Hong Kong Biotechnology news
Chronological news
Latest headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing …
6160
main company
Sharemaestro market context
Price above Trend Line
52 weeks +9.7%
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody …
9926
main company
Sharemaestro market context
Price below Trend Line
52 weeks -39.6% · Next-week setup positive 59.5%
Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 …
2162
main company
Sharemaestro market context
Trend signal active
52 weeks +10.8% · Next-week setup negative 44.2%
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday morning, declining 0.14% to 3,020.40 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by diagnostic imaging centers company Concord Medical Services (CCM) and Silver …
9688
main company
Sharemaestro market context
Trend signal started
52 weeks -38.0%
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab …
9926
main company
Sharemaestro market context
Price below Trend Line
52 weeks -39.6% · Next-week setup positive 59.5%
Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?
Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, …
9688
main company
Sharemaestro market context
Trend signal started
52 weeks -38.0%
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® …
1801
main company
Sharemaestro market context
Trend signal started
52 weeks -2.7%
Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zai Lab (ZLAB) stock is in focus after the company reported second quarter 2026 …
9688
main company
Sharemaestro market context
Trend signal started
52 weeks -38.0%
Shanghai Henlius Biotech, Inc. Announces Approval of Investigational New Drug Application for Clinical Trial of HLX43 for Injection in Combination with Bevacizumab for Treatment of Advanced or Metastatic Solid Tumours
2696
main company
Sharemaestro market context
Price below Trend Line
52 weeks -19.9%